APA (7th ed.) Citation

Reder, A. T., Centonze, D., Naylor, M. L., Nagpal, A., Rajbhandari, R., Altincatal, A., . . . de Moor, C. (2021). COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS drugs, 35(3), 317-330. https://doi.org/10.1007/s40263-021-00804-1

Chicago Style (17th ed.) Citation

Reder, Anthony T., et al. "COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies." CNS Drugs 35, no. 3 (2021): 317-330. https://doi.org/10.1007/s40263-021-00804-1.

MLA (9th ed.) Citation

Reder, Anthony T., et al. "COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies." CNS Drugs, vol. 35, no. 3, 2021, pp. 317-330, https://doi.org/10.1007/s40263-021-00804-1.